November 1, 2019

IntegriChain Presents Annual Customer Awards to Akcea Therapeutics, GSK, Johnson & Johnson and Spark Therapeutics

Awards Presented for Commercialization and Innovation at IntegriChain’s Access Insights Conference 

Philadelphia, PA, November 1, 2019– IntegriChain, a leading life sciences commercial data and analytics company that helps patients start therapy faster and stay on therapy longer, today announced that the Company presented its annual customer awards last week at the Access Insights Conference. The company awards included Best Commercialization Launch awarded to Spark Therapeutics, the Trade & Channel Innovator awarded to GSK, and the Trailblazer of the Year awarded to Akcea Therapeutics. An individual award, the ICyte Power User Award, was presented to Allyson S. Johnston, Manager, Trade & Patient Access Analytics, for Johnson & Johnson.

“Our entire team is excited to present our customer awards to Life Sciences groundbreakers who share our mission to save patient days of therapy,” said IntegriChain Co-Founder and CEO Kevin Leininger. “We are very proud to have meaningful partnerships with our innovative customers as we continue to enhance and expand our Life Sciences data and analytics platform for commercialization and market access, and we are thrilled to highlight and honor the outstanding impact on patients being made by Spark, GSK, Akcea, and Johnson & Johnson and the critical therapies they offer.”

I love working with IntegriChain to provide data-driven insights to my wide array of business partners, each with their own unique needs, including Trade, Channel Operations, Finance, Data Analytics, and Contracting,” said Johnston. “When I engage with my Integrichain Customer Success team, their knowledge of my business and the time and attention they devote to my many questions makes me feel like I am their only customer. This year’s conference demonstrated how much IntegriChain truly cares about incorporating individual customer feedback into their platform and is continually enhancing their data and analytics with the latest advances in data science. I am already looking forward to next year’s conference!”

Best Commercialization Launch
IntegriChain selected Spark Therapeutics for the Best Commercialization Launch of LUXTURNA® (voretigene neparvovec-rzyl). LUXTURNA, a one-time gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells, is the first gene therapy for a genetic disease approved in both the U.S. and EU. Spark has partnered with IntegriChain for Payer Contract Management and Outcomes-Based Contracting Professional Services for its gene therapy product.

Trade & Channel Innovator
IntegriChain selected GSK, a long-time customer, for the 2019 Trade & Channel Innovator Award. GSK has been at the forefront of innovation for IntegriChain’s Distribution solutions, including a recent partnership for the enhanced Distribution Contract Management offering.

Trailblazer of the Year
IntegriChain selected Akcea Therapeutics for the Trailblazer of the Year Award as the first adopter of the seamless ICyte Payer Platform, including Government Pricing, Rebate Management, Gross-To-Net Managed Services and SaaS-based Gross-to-Net Automation.

ICyte Power User 2019
IntegriChain named Allyson S. Johnston, Manager, Trade & Patient Access Analytics, for Johnson & Johnson as the ICyte Power User for 2019. Throughout the year, Johnston was a consistently engaged user on the ICyte data and analytics platform and with IntegriChain’s Customer Success team.

About IntegriChain
IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical access save as many patient days of therapy as possible. Our data-science-driven ICyte Platform and solutions uniquely focus on access challenges after the patient and provider commit to therapy. More than 165 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, and Pune, India. For more information, visit and our blog, or follow us on Twitter @IntegriChain and LinkedIn.

Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 |

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article